Complete response at 3 months was 79.6% (191/240), with duration-of-response estimates showing a gradual attrition over time ...

During a live event, Binod Dhakal, MD, discussed the evidence for targeting XPO1 and GPRC5D before BCMA CAR T-cell therapy in multiple myeloma.

Allogeneic hematopoietic cell transplantation (alloHCT) using tremtelectogene empogeditemcel (trem-cel), a CRISPR–Cas9–edited ...

Accelerated approval targets R/R MCL after prior BTK inhibition, addressing an area of high unmet need with limited established salvage standards. Phase 1/2 data at 320 mg QD showed ORR 52.4% and CR ...

Dr. Leal addresses diagnostic challenges with newer therapies, particularly tarlatamab's potential neurologic side effects ...

Dr. Leal introduces amifampridine, an FDA-approved oral potassium channel blocker that increases acetylcholine release at ...

Breakthrough therapy designation targets an unmet-need ACC population, positioning B7-H4 as a therapeutically actionable antigen in solid histology or high-grade transformed disease. Dose-escalation ...

KRd post-ASCT maintenance improved PFS and showed an OS advantage versus lenalidomide alone, supporting multidrug, extended-duration strategies despite modestly increased toxicity risk.

Experts discuss the critical role exercise plays in improving survival and quality of life in patients with cancer. For decades, the oncology community prioritized rest for patients undergoing active ...

In this closing segment on advanced renal cell carcinoma, Dr. Wulff invites final reflections on anticipated changes in treatment guidelines over the coming year. In this closing segment on advanced ...

RAINIER is a multicenter, open-label, multi-cohort phase 1b/2 dose-optimization study enrolling adults aged 18 years or older ...

Clinical care remains anchored in disease-specific expertise, but is augmented by wraparound services tailored to life stage.